Thats 12 percent of adults, which is a lot of people
In contrast to these results, a study using nationwide registry data from Sweden, Denmark, and Norwayinvolving 121,254 new GLP-1 RA users and 185,027 new SGLT-2 inhibitor users documented 557 intestinal obstruction events, with no significant correlation between GLP-1 RA use and increased intestinal obstruction risk, thereby refuting earlier safety concerns [12]
It is interesting to see these new oral medicines enter the market.
Next-generation protein-rich potato expressing the seed protein gene AmA1 is a result of proteome rebalancing in transgenic tuber
Cleavages by Glu-C were analysed based on the enzyme that was used for digestion
Common concerns regarding GLP-1 While GLP-1 medications offer hope, they are not without their own set of challenges: Weight regain Some patients experience weight regain once they discontinue GLP-1 therapy, especially if they have yet to make lasting lifestyle changes [6]